VR-23

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: VR-23
• 英文别名: 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline；7-Chloro-4-(4-((2,4-dinitrophenyl)sulfonyl)piperazin-1-yl)quinoline；7-chloro-4-[4-(2,4-dinitrophenyl)sulfonylpiperazin-1-yl]quinoline
• 化学式: C₁₉H₁₆ClN₅O₆S
• 分子量: 477.885
• InChiKey: PDQVZPPIHADUOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  154
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4,7-二氯喹啉 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 7.0h， 生成 VR-23
  参考文献：
  名称：

  [EN] QUINOLINE SULFONYL DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS DE LA SULFONYLE QUINOLÉINE ET APPLICATIONS ASSOCIÉES

  摘要：

  本公开涉及喹啉磺酰化合物，包含这些化合物的组合物及其用途，特别是用于癌症治疗。具体而言，本公开包括式（I）的化合物，以及其组合物和用途。

  公开号：

  WO2014134705A1

文献信息

• Use of a quinoline sulfonyl compound for treatment of inflammation, inflammatory disorders, autoimmune disorders and malaria
  申请人：Lee Hoyun

  公开号：US11357774B2

  公开（公告）日：2022-06-14

  The present application relates to uses of 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline (VR23) or optionally a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of malaria or for treatment of a disease, disorder or condition treatable by reducing or inhibiting the secretion of a pro-inflammatory cytokine and/or reducing myeloperoxidase such as inflammation, an inflammatory disorder or autoimmune disease.

  本申请涉及 7-氯-4-(4-(2,4-二硝基苯基磺酰基)哌嗪-1-基)喹啉 (VR23) 或其药学上可接受的盐、溶液剂或原药的用途，用于治疗疟疾或治疗可通过减少或抑制促炎细胞因子的分泌和/或减少髓过氧化物酶来治疗的疾病、紊乱或病症，如炎症、炎症性紊乱或自身免疫性疾病。
• QUINOLINE SULFONYL DERIVATIVES AND USES THEREOF
  申请人：Advanced Medical Research Institute Of Canada

  公开号：EP2964625A1

  公开（公告）日：2016-01-13
• Quinoline Sulfonyl Derivatives And Uses Thereof
  申请人：ADVANCED MEDICAL RESEARCH INSTITUTE OF CANADA

  公开号：US20150376132A1

  公开（公告）日：2015-12-31

  The present disclosure relates to quinoline sulfonyl compounds, compositions comprising these compounds and their use, in particular for the treatment of cancer. In particular, the present disclosure includes compounds of Formula (I), and compositions and uses thereof:
• USE OF A QUINOLINE SULFONYL COMPOUND FOR TREATMENT OF INFLAMMATION, INFLAMMATORY DISORDERS, AUTOIMMUNE DISORDERS AND MALARIA
  申请人：Lee Hoyun

  公开号：US20200281920A1

  公开（公告）日：2020-09-10

  The present application relates to uses of 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline (VR23) or optionally a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of malaria or for treatment of a disease, disorder or condition treatable by reducing or inhibiting the secretion of a pro-inflammatory cytokine and/or reducing myeloperoxidase such as inflammation, an inflammatory disorder or autoimmune disease.
• USE OF PROTEASOME INHIBITOR AND ALPHAVIRUS IN PREPARATION OF ANTI-TUMOR MEDICAMENT
  申请人：GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.

  公开号：US20210228660A1

  公开（公告）日：2021-07-29

  Use of a proteasome inhibitor and an alphavirus in the preparation of an anti-tumor medicament. The proteasome inhibitor can be used to prepare an alphavirus anti-tumor synergist. A pharmaceutical composition comprising a proteasome inhibitor and an alphavirus, including a pharmaceutical kit comprising the proteasome inhibitor and the alphavirus, and use of the proteasome inhibitor and the virus in the treatment of tumors, particularly tumors insensitive to the alphavirus.